NBP1-05096 MDA-treated LDL antibody

See related secondary antibodies

Search for all "MDA-treated LDL"

0.1 mg / €450.00
Please visit the country specific website of Acris Antibodies or contact your local Distributor to buy this product.

Quick Overview

Mouse anti MDA-treated LDL

NBP1-05096

Product Description for MDA-treated LDL

Mouse anti MDA-treated LDL.
Presentation: Purified
Product is tested for Enzyme Immunoassay, Western blot / Immunoblot.

Properties for MDA-treated LDL

Product Category Primary Antibodies
Quantity 0.1 mg
Presentation Purified
Applications E, WB
Clonality Polyclonal
Host Mouse
Isotype IgG1
Shipping to Not USA/Canada
PDF datasheet View Datasheet
Manufacturer Novus Biologicals Inc.

Datasheet Extract

Application ELISA, Western Blot, ELISA and Western Blot, ELISA 1:8000, Western Blot ,
Background Low-density lipoprotein (LDL) is the carrier protein for cholesterol in the blood. LDL binds to its receptor on the capillary walls and thereby mediates the uptake and clearance of cholesterol from the circulation. In atherosclerotic lesions oxidatively modified LDL is found and oxidized LDL is specifically recognized and ingested by macrophages via scavenger receptor A and CD36. Oxidized LDL may be a marker of atherosclerosis but the precise changes in oxidized LDL are not well described. MDA-treated LDL appear to be different from LDL oxidized by other means.
Concentration 1 mg/ml
General Readings
  1. Palinski W, Ylä-Herttuala S, Rosenfeld ME, Butler SW, Socher SA, Parthasarathy S, et al. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis. 1990 May-Jun;10(3):325-35. PubMed PMID: 1693068.
  2. Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet. 1993 Apr 10;341(8850):923-5. PubMed PMID: 8096266.
  3. Binder CJ, Hörkkö S, Dewan A, Chang MK, Kieu EP, Goodyear CS, et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med. 2003 Jun;9(6):736-43. Epub 2003 May 12. PubMed PMID: 12740573.
Storage Store at 4C. Do not freeze.
Format
Purification:
protein A purified
Buffer System:
15mM Sodium Azide
Purity:
protein A purified
State:
Purified
Specificity
Specificity:
Reacts with MDA-treated LDL but not with native LDL

Accessory Products

  • LinkedIn